Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVD-003 in Congenital Pseudarthrosis of the Tibia (Pediatric)
2024-515478-29-00Phase 2Completed
- Sponsor
- Novadip Biosciences
- Start
- Nov 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of NVD-003 in congenital pseudarthrosis of the tibia (CPT), sponsored by Novadip Biosciences. Primary endpoints: Short-term safety of ATC and NVD-003, Mid long-term safety of NVD-003 and reintervention rate and 1 more. Started Nov 2022; status: completed.
02
Drugs
NVD-003
03
Conditions
congenital pseudarthrosis of the tibia (CPT)
Beyond the preview
Go deeper on 2024-515478-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515478-29-00.